Clinical trialNCT04968574CompletedPhase 2Interventional

A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

SponsorEndeavor Biomedicines, Inc.Enrollment41Idiopathic Pulmonary Fibrosis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 2, randomized, placebo controlled, multi-center study in subjects with mild to moderate IPF. Eligible subjects will be randomized to receive placebo or ENV-101 as a daily oral dose for 12 consecutive weeks of treatment. Following treatment, subjects will be observed for an additional 6 weeks.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

John Huetsch, M.D.
Endeavor Biomedicines
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Research Site
Liverpool, New South Wales, Australia
Research Site
Benowa, Queensland, Australia
Research Site
Box Hill, Victoria, Australia
Research Site
Clayton, Victoria, Australia

Canada

Research Site
Vancouver, British Columbia, Canada
Research Site
Sherbrooke, Quebec, Canada

Malaysia

Research Site
Batu Caves, Malaysia
Research Site
Kota Bharu, Malaysia
Research Sire
Kuala Lumpur, Malaysia
Research Site
Kuala Lumpur, Malaysia
Research Site
Kuala Lumpur, Malaysia

Mexico

Research Site
Monterrey, Nuevo León, Mexico
Research Site
Monterrey, Nuevo León, Mexico
Research Site
San Nicolás de los Garza, Nuevo León, Mexico
Research Site
Chihuahua City, Mexico
Research Site
Mexico City, Mexico
Research Site
Mexico City, Mexico
Research Site
Oaxaca City, Mexico
Research Site
Puebla City, Mexico

South Korea

Research Site (namdong District)
Incheon, South Korea
Research Site (bundang District)
Seongnam, South Korea
Research Site (gangnam District)
Seoul, South Korea
Research Site (seongbuk District)
Seoul, South Korea
Research Site (songpa District)
Seoul, South Korea

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PlaceboTaladegib

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 26 Aug 2021
Primary completion: 30 Nov 2023
Completion: 30 Nov 2023
Last update posted: 2 Dec 2024
Registered enrollment: 41
Registry id: NCT04968574

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.